177-LUTETIUM-PSMA-617 (Pluvicto™) for Prostate Cancer: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Novartis

DelveInsight has released a comprehensive report titled "177-LUTETIUM-PSMA-617 (Pluvicto™) Market Forecast," offering a thorough examination and predictive insights into the Vyzulta market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of Vyzulta in the therapeutics landscape for Prostate Cancer across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of Vyzulta, encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

Get a detailed overview of the evolving trends in the Prostate Cancer therapeutic market @
https://www.delveinsight.com/report-store/177-lutetium-psma-617-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

177-LUTETIUM-PSMA-617 (Pluvicto™) Drug Insights
Lu-PSMA, an investigational drug falling within the category of radiopharmaceuticals, represents a novel approach in cancer therapy. This experimental compound combines 177lutetium, a potent radionuclide serving as the "warhead," with PSMA-617, a peptide acting as the targeted delivery system to cancer cells-resembling a precision "missile." The intricacies of Lu-PSMA place it within the realm of theranostics, a burgeoning field in cancer treatment that integrates therapeutic and diagnostic components.

To elaborate, the 177 lutetium component of Lu-PSMA contributes the radioactive element crucial for its therapeutic effect. This serves as the active agent or "warhead," delivering targeted radiation to cancer cells. On the other hand, PSMA-617 functions as the carrier peptide, guiding the warhead specifically to cancerous tissues, ensuring a precise and targeted approach to treatment. This innovative combination of a radioactive isotope and a targeted delivery mechanism underscores the potential of Lu-PSMA in enhancing the effectiveness of cancer therapy.

Theranostics, while initially challenging to grasp, is poised to become a focal point in the evolving landscape of cancer treatment. It represents a paradigm shift, emphasizing the integration of therapeutic and diagnostic capabilities within a single agent. The administration of Lu-PSMA involves intravenous injection, marking a step forward in the development of advanced cancer therapies. As research progresses, Lu-PSMA stands as a promising contender, offering a glimpse into the future of precision medicine for cancer.

177-LUTETIUM-PSMA-617 (Pluvicto™) Drug - Regulatory Development.
In March 2022, the FDA granted approval to Pluvicto™ (previously known as 177Lu-PSMA-617) for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer. This significant regulatory milestone marked a pivotal moment in the medical landscape, offering a targeted therapeutic option for individuals facing this challenging form of prostate cancer.

Notably, Pluvicto™ is undergoing continuous development by Novartis, having been initially acquired from the Purdue-startup company Endocyte. Beyond its current approval, ongoing research and development efforts aim to explore the potential applications of Pluvicto™ for other indications within the realm of prostate cancer. The collaboration between Novartis and Endocyte exemplifies the dynamic nature of pharmaceutical innovation, with the goal of expanding treatment options and improving outcomes for patients with diverse prostate cancer conditions.

Get a detailed overview of the 177-LUTETIUM-PSMA-617 drug and stay ahead of the competition by leveraging key insights @
https://www.delveinsight.com/sample-request/177-lutetium-psma-617-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Key Highlights of the 177-LUTETIUM-PSMA-617 (Pluvicto™) Market Report
• The report includes a projected assessment of Vyzulta sales for Prostate Cancer up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Prostate Cancer.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on Vyzulta for Prostate Cancer.

Why 177-LUTETIUM-PSMA-617 (Pluvicto™) Market Report?
• The projected market data for Vyzulta in the context of Prostate Cancer will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of Vyzulta, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for Vyzulta will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the Vyzulta market in the field of Prostate Cancer across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Prostate Cancer. This multifaceted approach ensures a comprehensive understanding of the Vyzulta market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for Vyzulta will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of Vyzulta.

Request the Sample PDF to Learn More About the Key Offerings of the 177-LUTETIUM-PSMA-617 Market Report @
https://www.delveinsight.com/sample-request/177-lutetium-psma-617-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Related Reports By DelveInsight
Prostate Cancer Pipeline Insight
DelveInsight's "Prostate Cancer Pipeline Insight" report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Prostate Cancer Therapeutics market include Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, and Cellbion. Visit & explore how the Prostate Cancer therapeutics pipeline is evolving, at: https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry @ https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

This release was published on openPR.